Brean Capital initiates coverage on Pernix Therapeutics (NASDAQ: PTX) with a Buy rating and a price target of $17.00.Analyst Difei ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE